Disclosures for "Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT"
-
Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strongbridge. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.
-
Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Powell Mansfield. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta (now J&J). Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Bril has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Bril has received research support from UCB. The institution of Dr. Bril has received research support from Argenx. The institution of Dr. Bril has received research support from Momenta (now J&J). The institution of Dr. Bril has received research support from Immunovant. The institution of Dr. Bril has received research support from Alexion. The institution of Dr. Bril has received research support from Takeda. The institution of Dr. Bril has received research support from Grifols. The institution of Dr. Bril has received research support from CSL. The institution of Dr. Bril has received research support from Octapharma. The institution of Dr. Bril has received research support from Akcea. The institution of Dr. Bril has received research support from Ionis. The institution of Dr. Bril has received research support from Viela Bio (now Horizon). Dr. Bril has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Immune Sciences. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arcellx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Genentech. The institution of Dr. Habib has received research support from Regeneron.
-
Dr. Claeys has nothing to disclose.
-
The institution of Dr. Hussain has received research support from Alnylam Pharma.
-
Dr. Sahagian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sahagian has received intellectual property interests from a discovery or technology relating to health care.
-
Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Elena Cortes-Vicente has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Elena Cortes-Vicente has received research support from UCB Pharma. The institution of Elena Cortes-Vicente has received research support from Instituto de Salud Carlos III (España).
-
Edward Brauer has received personal compensation for serving as an employee of argenx. Edward Brauer has stock in argenx.
-
Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.
-
Dr. Gelinas has received personal compensation for serving as an employee of argenx. Dr. Gelinas has stock in argenx.
-
Dr. Liu has stock in argenx.
-
Dr. Jimenez has nothing to disclose.
-
Mrs. Masschaele has received personal compensation for serving as an employee of argenx. An immediate family member of Mrs. Masschaele has received personal compensation for serving as an employee of argenx. Mrs. Masschaele has stock in argenx. An immediate family member of Mrs. Masschaele has stock in argenx.
-
Dr. Mantegazza has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Mantegazza has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Mantegazza has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Mantegazza has received research support from ERAPERMED, EU.
-
Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for argenx. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adivo. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. The institution of Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Andreas Meisel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer/BMS. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Axunio. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Desitin. Andreas Meisel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genpharm. The institution of Andreas Meisel has received research support from Alexion. The institution of Andreas Meisel has received research support from argenx. The institution of Andreas Meisel has received research support from Octapharma. The institution of Andreas Meisel has received research support from Deutsche Myasthenie Gesellschaft. The institution of Andreas Meisel has received research support from Deutsche Forschungsgemeinschaft . The institution of Andreas Meisel has received research support from Bundesministerium für Wissenschaft und Forschung. The institution of Andreas Meisel has received research support from Leducq Foundation. The institution of Andreas Meisel has received research support from Einstein Stiftung Berlin. Andreas Meisel has received publishing royalties from a publication relating to health care. Andreas Meisel has received publishing royalties from a publication relating to health care. Andreas Meisel has a non-compensated relationship as a Chairman, Medical Advisory Board with Deutsche Myasthenie Gesellschaft that is relevant to AAN interests or activities. Andreas Meisel has a non-compensated relationship as a Chairman with Berliner Schlaganfall Gesellschaft that is relevant to AAN interests or activities.
-
Dr. Sun has nothing to disclose.
-
Prof. Attarian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI, Pfizer LFB, Alnylam Biogen Argenx, UCB Alexion, Astrazenica, Amicus, Janssen, Novartis, Roche. Prof. Attarian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SANOFI, Biogen,Alnylam, Argenix, USB, Alexion Astrazenica, Janssen, Roche. The institution of Prof. Attarian has received research support from National Institut of Health .